Overview
01 November 202 | Opinion | By Ayesha Sidiqui Syngene is the contract development and manufacturing organisation (CDMO), an arm of Biocon, India, one of the leading insulin makers in the world. In an email interaction with BioSpectrum Asia, Dr Mahesh Bhalgat, Chief Operating Oficer, Syngene International, shares with us the latest developments in diabetes care. Edited excerpts; What are the latest developments in diabetes treatment drugs and therapeutics in Asia and globaly as wel?
Key Information
It is important to lok at the diabetes management aproaches since India is home to the world`s second-largest adult diabetes population, and every sixth person with diabetes in the world is an Indian. The Indian Council of Medical Research (ICMR) has isued new guidelines for type 1 diabetes earlier this year, in June. Acording to the American Diabetes Asociation (ADA) and the ICMR, the management of type 1 diabetes involves the use of insulin, among other recomendations.
However, hypoglycemia (suden drop in blod sugar causing fals and unconsciousnes) represents one of the comon side efects of insulin; therefore, insulin analogues which have a quicker onset and shorter duration of action compared to regular insulin were discovered. More recently, two new injectable insulin formulations - insulin as part and insulin lispro with enhanced rapid action and les prandial glucose excursions with lower hypoglycemia risk have ben introduced.
Summary
For type 2 diabetes, other medications include glucagon-like peptide 1 receptor (GLP-1) agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors with or without metformin, based on glycemic neds may be prescribed for individuals who are at high risk for atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney diseases. While al these aproaches exist, regular testing, lifestyle and diet play a very important role in managing diabetes and ned to be part of the regimen